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Background: A possible interference between lupus anticoagulant (LAC), a well characterized 
clotting inhibitor, in the International Normalized Ratio (INR) determination during oral antico-
agulation (OA) has been reported in the literature. Few data are available about the relationship 
between this kind of interference and the daily clinical management of oral anticoagulation. 
The aim of the study is to evaluate the role of two different thromboplastins–RecombiPlasTin 
2G and HepatoComplex–in the determination of INR values of several patients’ ongoing OA 
for a previous thrombotic disorder with and without positivity to LAC, and to evaluate possible 
interferences in the daily therapeutic approach.
Patients and methods: We selected 16 patients (13 females and 3 males, mean age 
59 ± 16 years) with LAC positivity ongoing OA and 11 control subjects (7 females and 4 males, 
mean age 58 ± 14.5 years) with similar characteristics (ie, ethnic background and weight) 
with LAC negativity ongoing OA. 165 assays for INR determination were analyzed from both 
groups. Statistical analysis was performed using STATA 10 software. P values were considered 
significant if ,0.05.
Results: Mean values of INR for patients with LAC positivity were 3.79 ± 1.63 when tested 
with RecombiPlasTin 2G vs 3.18 ± 1.15 when tested with HepatoComplex (P , 0.001, s); 
while mean values of INR for patients with antiphospholipid syndrome (APS) with LAC 
negativity were 3.54 ± 1.39 when tested with RecombiPlasTin 2G vs 3.23 ± 1.14 when tested 
with HepatoComplex (P , 0.002, s). An INR value . than 4.5 was found in 31/165 samples 
in 9 subjects, 8 patients with LAC positivity, and 1 control group subject with LAC negativity. 
There was a great difference in INR values in these subjects if we use the common thrombo-
plastin (ie, RecombiPlasTin 2G) with a INR range varying from 5.14 ± 0.35 vs 3.79 ± 0.38 if 
we use another thromboplastin (ie, HepatoComplex) (P , 0.001, s). A change in the therapeutic 
approach for OA is possible in these cases because different INR values were obtained using 
different thromboplastins.
Discussion: Our data confirm that INR evaluation does not reveal significant changes also 
if tested with two different thromboplastins, for patients ongoing OA with and without LAC 
positivity, when the INR value is , than 4. Over this INR value there is a significant difference 
in patients with LAC positivity if we use a different thromboplastin for the INR determination. 
For this reason values obtained by RecombiPlasTin 2G need to be confirmed and matched with 
another thromboplastin (ie, HepatoComplex). This approach may be useful in order to have a 
good INR testing for the chronic long-term treatment with OA in particular in patients with 
LAC positivity.
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Introduction
Oral anticoagulation (OA) is the gold standard therapy for 
long-term treatment of thrombotic disorders.1 OA is based 
on the administration of antivitamin K (AVK) drugs that are 
able to induce a reduced intake of vitamin K and a following 
reduced synthesis of clotting factors (ie, clotting factors 
II, VII, IX, X). In particular, reductions of synthesized 
prothrombin (ie, clotting factor II), induces a prolonged 
prothrombin time (PT).2
PT is used in the daily clinical management of patients 
ongoing OA, and in the last years the International Normal-
ized Ratio (INR) of PT is used to monitor patients ongoing 
OA.3 Moreover, OA monitoring is performed worldwide 
by INR.3
However, because of several reagents used to perform the 
PT INR, (ie, commercial thromboplastins), we sometimes 
observe differences in the INR evaluation.4
Lupus anticoagulant (LAC) is an acquired clotting inhibi-
tor that is frequently associated with primary or secondary 
antiphospholipid syndrome (APS) and is able to alter mainly 
activated partial thromboplastin time (aPTT) and in few cases 
PT INR too.5 However, APS associated with LAC is fre-
quently associated with thrombotic events and the long term 
antithrombotic treatment is usually performed by OA.6,7
Because the presence of LAC may alter also INR value 
during prolonged OA, a misunderstanding in the daily clinical 
management of patients with positivity to LAC ongoing OA 
is possible because of this kind of interference. Moreover, 
in these cases, if we suppose an interference by LAC in the 
INR value, it is necessary to perform the INR assay with 
another thromboplastin less sensitive to an acquired inhibitor 
as LAC,8 as suggested several authors.
The aim of this study is to evaluate differences and effects 
of two different thromboplastins, to monitor INR during OA 
in patients with LAC positivity and previous thrombotic 
events, and to evaluate if there is a different clinical approach 
if this interference is present. Another aspect is related to the 
possible alteration induced by the interference on the dose-
response administration of AVK drugs that may interfere in 
the frail balance of OA management due to the the risk of 
thrombotic and\or hemorragic events.
Patients and methods
Patients
We selected 16 patients (13 females and 3 males, mean age 
59 ± 6 years) with LAC positivity after a thrombotic episode 
and 11 patients (7 females and 4 males 58 ± 14.5 years) 
with LAC negativity after a thrombotic event (ie, venous 
  thromboembolism, ischemic stroke, acute coronary   syn  drome), 
as a control group.
All patients were ongoing OA and we analyzed INR 
samples from all patients of both groups with two different 
thromboplastin (ie, RecombiPlasTin 2G, common thrombo-
plastin, and HepatoComplex, a less sensitive thromboplastin 
to acquired inhibitors). We performed this observational 
analysis for 6 months.
Each patient performed nearly 6.1 blood samples to 
monitor INR during OA for a total of 165 samples in the 
study population.
As control group we selected 11 subjects with similar 
characteristics (age, ethnic background, weight) ongoing 
OA but with LAC negativity.
Each control subject performed nearly 5.6 blood samples 
in the observational period.
We do not divide patients into INR range groups because 
this kind of division had been performed in other reports.8
Methods
Venous blood samples were taken from antecubital vein 
and put in a tube with sodium citrate 1/9 v/v. All selected 
subjects in the study performed consecutive blood sam-
ples for the evaluation of INR for OA with two different 
commercial thromboplastins, ie, RecombiPlasTin 2G 
(Instrumentation Laboratory, Milan, Italy) and HepatoCom-
plex IL (Instrumention Laboratory). INR evaluation was 
performed with coagulometer ACL TOP (Instrumentation 
Laboratory).
LAC testing was performed according to international 
guidelines and with common commercial kits.9 LAC deter-
mination was performed at the time of diagnosis and after 
12 weeks according to the international guidelines; further 
determinations are considered after 6–12 months and\or after 
clinical resolution of thrombotic disorders.
Statistical analysis
Data were described as number and percentage or mean 
and standard deviation where appropriate. Differences were 
explored with Mann–Whitney u test and Student’s t-test, 
where appropriate. P values were considered significant 
if less than 0.05. Analysis was performed with STATA 10 
(Stata Corp, College Station, TX).
Results
Mean values of INR for patients with LAC positivity 
were 3.79 ± 1.63 when tested with RecombiPlasTin 
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(P , 0.001, s), while mean values of INR for patients 
with LAC negativity were 3.54 ± 1.39 when tested with 
RecombiPlasTin 2G vs 3.30 ± 1.07 when tested with 
HepatoComplex (P , 0.002, s).
INR value . than 4.0, so suggesting an overdose of AVK 
drugs, was found in 31/165 samples by 9 subjects, 8 patients 
with LAC positivity, and 1 control group subject with LAC 
negativity.
The mean INR values of patients with LAC   positivity were 
5.14 ± 0.35 when tested with RecombiPlasTin vs 3.79 ± 0.38 
when tested with HepatoComplex (P , 0.001, s), so confirm-
ing an interference of the acquired inhibitor LAC in the INR 
determination, which may influence the administered doses 
of AVK drugs in the daily therapeutic approach to OA.
Concerning the AVK doses, patients with LAC positivity 
had weekly doses of 28.55 mg of warfarin vs 27.8 mg for 
LAC negativity (P 0.48, ns). Data are reported as cases vs 
controls linear regression in Figure 1.
Discussion
OA is the gold standard long-term treatment for thrombotic 
disorders also if due to acquired thrombophilia for the pres-
ence of APS.1 LAC is the more common acquired clotting 
inhibitor in APS and it is able to alter INR (besides aPTT).10,11 
However, the literature suggests that this kind of interfer-
ence may appear more frequently if INR value is higher 
than 4.0.4
Our data confirm that patients ongoing OA for a throm-
botic event without LAC positivity usually have good control 
of INR with a common reagent (ie, RecombiPlasTin 2G, as 
thromboplastin); yet, those with LAC positivity show less 
control of INR values because of the interference of LAC. 
However, this aspect seems to be relevant for INR values 
greater than 4, while values less than 4 did not determine 
significant alteration in the laboratory assays. Subjects with 
LAC positivity that show INR values greater than 4 during 
OA may benefit from a matched INR control with another 
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Figure 1 Cases vs controls linear regression of INR monitoring with or without lupus anticoagulant positivity with two different thromboplastins.Journal of Blood Medicine
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thromboplastin (ie, HepatoComplex) that has less sensibility 
to acquired clotting inhibitors as LAC. Alternatively for these 
values it may suggested to perform assays for Xa levels in 
order to exclude other types of interferences in the manage-
ment of antithrombotic therapies.8
So, two different INR values due to the interference of an 
acquired inhibitor as LAC may also alter the daily clinical 
approach if we need to choose appropriate doses of AVK 
drugs for long-term OA. From a clinical point of view, we 
should consider that this kind of patient might go on a more 
frequent control of INR during OA in order to avoid mistakes 
in chronic long term therapy, although our data did not under-
line this aspect. This approach, using another thromboplastin 
less sensitive to acquired inhibitor as LAC, permitted us to 
have good control of OA in the clinical setting avoiding 
thrombotic and hemorragic complications. We should con-
sider, in fact, that a misunderstanding in the administered 
AVK drugs’ doses may reflect a possible increased trend to 
develop thrombotic and/or hemorragic complications, which 
are the most common complications for patients ongoing 
long term treatment with AVK drugs.
In conclusion, because the possible interference of 
acquired clotting inhibitors, such as LAC, in the INR 
monitoring for OA, we suggest monitoring INR with a less 
sensitive thromboplastin such as HepatoComplex to avoid 
thrombotic and hemorragic complications. In particular, if the 
INR value is greater than 4 as reported by our data, a different 
approach in the administration of AVK drug is required.
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